EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Intensity Therapeutics's Enterprise Value is $59.18 Mil.
Intensity Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-10.67 Mil. Therefore, Intensity Therapeutics's EV-to-FCF for today is -5.55.
The historical rank and industry rank for Intensity Therapeutics's EV-to-FCF or its related term are showing as below:
INTS'
s EV-to-FCF Range Over the Past 10 Years
Min: -75.27 Med: 0 Max: 0
Current: -5.46
INTS's EV-to-FCF is ranked worse than 100% of 367
companies
in the Biotechnology industry
Industry Median: 9.77
vs INTS: -5.46
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Intensity Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Intensity Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intensity Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intensity Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Intensity Therapeutics's EV-to-FCF falls into.
Intensity Therapeutics's current Enterprise Value is $59.18 Mil.
Intensity Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Intensity Therapeutics's PE Ratio for today is calculated as:
Intensity Therapeutics's share price for today is $5.0616.
Intensity Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.171.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Intensity Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Intensity Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Intensity Therapeutics (Intensity Therapeutics) Business Description
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INTS has been successfully added to your 